1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Atherosclerosis	_	_	NN	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	common	_	_	JJ	_	_	_	_	_
5	pathology	_	_	NN	_	_	_	_	_
6	that	_	_	WDT	_	_	_	_	_
7	affects	_	_	VBZ	_	_	_	_	_
8	large	_	_	JJ	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	medium	_	_	JJ	_	_	_	_	_
11	arteries	_	_	NNS	_	_	_	_	_
12	leading	_	_	VBG	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	variety	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	cardiovascular	_	_	JJ	_	_	_	_	_
18	events	_	_	NNS	_	_	_	_	_
19	that	_	_	WDT	_	_	_	_	_
20	can	_	_	MD	_	_	_	_	_
21	also	_	_	RB	_	_	_	_	_
22	be	_	_	VB	_	_	_	_	_
23	fatal	_	_	JJ	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	therefore	_	_	RB	_	_	_	_	_
26	representing	_	_	VBG	_	_	_	_	_
27	a	_	_	DT	_	_	_	_	_
28	serious	_	_	JJ	_	_	_	_	_
29	public	_	_	JJ	_	_	_	_	_
30	health	_	_	NN	_	_	_	_	_
31	problem	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	Atherosclerosis	_	_	NN	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	characterized	_	_	VBN	_	_	_	_	_
4	by	_	_	IN	_	_	_	_	_
5	progressive	_	_	JJ	_	_	_	_	_
6	lipid	_	_	NN	_	_	_	_	_
7	deposition	_	_	NN	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	arterial	_	_	JJ	_	_	_	_	_
11	wall	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	plaque	_	_	NN	_	_	_	_	_
14	induction	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	possible	_	_	JJ	_	_	_	_	_
17	further	_	_	JJR	_	_	_	_	_
18	progression	_	_	NN	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	state	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	so-called	_	_	JJ	_	_	_	_	_
24	unstable	_	_	JJ	_	_	_	_	_
25	plaque	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Advanced	_	_	JJ	_	_	_	_	_
2	plaques	_	_	NNS	_	_	_	_	_
3	usually	_	_	RB	_	_	_	_	_
4	acquire	_	_	VBP	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	fibrous	_	_	JJ	_	_	_	_	_
7	cap	_	_	NN	_	_	_	_	_
8	that	_	_	WDT	_	_	_	_	_
9	separates	_	_	VBZ	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	plaque	_	_	NN	_	_	_	_	_
12	from	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	surrounding	_	_	VBG	_	_	_	_	_
15	milieu	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	plays	_	_	VBZ	_	_	_	_	_
18	a	_	_	DT	_	_	_	_	_
19	stabilizing	_	_	VBG	_	_	_	_	_
20	role	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Destabilization	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	plaques	_	_	NNS	_	_	_	_	_
4	leads	_	_	VBZ	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	their	_	_	PRP$	_	_	_	_	_
7	rupture	_	_	NN	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	subsequent	_	_	JJ	_	_	_	_	_
10	thrombus	_	_	NN	_	_	_	_	_
11	formation	_	_	NN	_	_	_	_	_
12	that	_	_	WDT	_	_	_	_	_
13	can	_	_	MD	_	_	_	_	_
14	lead	_	_	VB	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	dangerous	_	_	JJ	_	_	_	_	_
17	events	_	_	NNS	_	_	_	_	_
18	such	_	_	JJ	_	_	_	_	_
19	as	_	_	IN	_	_	_	_	_
20	acute	_	_	JJ	_	_	_	_	_
21	coronary	_	_	JJ	_	_	_	_	_
22	syndrome	_	_	NN	_	_	_	_	_
23	(	_	_	-LRB-	_	_	_	_	_
24	ACS	_	_	NN	_	_	_	_	_
25	)	_	_	-RRB-	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	stroke	_	_	NN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	Advanced	_	_	JJ	_	_	_	_	_
2	complicated	_	_	JJ	_	_	_	_	_
3	plaques	_	_	NNS	_	_	_	_	_
4	are	_	_	VBP	_	_	_	_	_
5	also	_	_	RB	_	_	_	_	_
6	characterized	_	_	VBN	_	_	_	_	_
7	by	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	formation	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	necrotic	_	_	JJ	_	_	_	_	_
13	core	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	pathological	_	_	JJ	_	_	_	_	_
16	vascular	_	_	JJ	_	_	_	_	_
17	remodeling	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	plaque	_	_	NN	_	_	_	_	_
20	neovascularization	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	calcification	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Elevated	_	_	VBN	_	_	_	_	_
2	low-density	_	_	JJ	_	_	_	_	_
3	lipoprotein	_	_	NN	_	_	_	_	_
4	(	_	_	-LRB-	_	_	_	_	_
5	LDL	_	_	NN	_	_	_	_	_
6	)	_	_	-RRB-	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	known	_	_	VBN	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	be	_	_	VB	_	_	_	_	_
11	associated	_	_	VBN	_	_	_	_	_
12	with	_	_	IN	_	_	_	_	_
13	atherosclerosis	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	is	_	_	VBZ	_	_	_	_	_
16	identified	_	_	VBN	_	_	_	_	_
17	as	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	major	_	_	JJ	_	_	_	_	_
20	source	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	lipids	_	_	NNS	_	_	_	_	_
23	accumulating	_	_	VBG	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	atherosclerotic	_	_	JJ	_	_	_	_	_
26	plaques	_	_	NNS	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Circulating	_	_	VBG	_	_	_	_	_
2	modified	_	_	VBN	_	_	_	_	_
3	LDL	_	_	NN	_	_	_	_	_
4	has	_	_	VBZ	_	_	_	_	_
5	increased	_	_	VBN	_	_	_	_	_
6	atherogenicity	_	_	NN	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	comparison	_	_	NN	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	native	_	_	JJ	_	_	_	_	_
11	LDL	_	_	NNP	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	Chemical	_	_	JJ	_	_	_	_	_
2	modification	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	LDL	_	_	NNP	_	_	_	_	_
5	likely	_	_	RB	_	_	_	_	_
6	plays	_	_	VBZ	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	prominent	_	_	JJ	_	_	_	_	_
9	role	_	_	NN	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	atherosclerosis	_	_	NN	_	_	_	_	_
12	development	_	_	NN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	Besides	_	_	IN	_	_	_	_	_
2	elevated	_	_	VBN	_	_	_	_	_
3	LDL	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	chronic	_	_	JJ	_	_	_	_	_
6	inflammation	_	_	NN	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	now	_	_	RB	_	_	_	_	_
9	considered	_	_	VBN	_	_	_	_	_
10	as	_	_	IN	_	_	_	_	_
11	another	_	_	DT	_	_	_	_	_
12	crucial	_	_	JJ	_	_	_	_	_
13	pro-atherogenic	_	_	JJ	_	_	_	_	_
14	mechanism	_	_	NN	_	_	_	_	_
15	that	_	_	WDT	_	_	_	_	_
16	can	_	_	MD	_	_	_	_	_
17	even	_	_	RB	_	_	_	_	_
18	precede	_	_	VB	_	_	_	_	_
19	lipid	_	_	JJ	_	_	_	_	_
20	entry	_	_	NN	_	_	_	_	_
21	into	_	_	IN	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	arterial	_	_	JJ	_	_	_	_	_
24	intima	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	has	_	_	VBZ	_	_	_	_	_
3	been	_	_	VBN	_	_	_	_	_
4	proposed	_	_	VBN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	disturbances	_	_	NNS	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	hemodynamic	_	_	JJ	_	_	_	_	_
9	forces	_	_	NNS	_	_	_	_	_
10	that	_	_	WDT	_	_	_	_	_
11	are	_	_	VBP	_	_	_	_	_
12	especially	_	_	RB	_	_	_	_	_
13	likely	_	_	JJ	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	occur	_	_	VB	_	_	_	_	_
16	at	_	_	IN	_	_	_	_	_
17	atheroprone	_	_	JJ	_	_	_	_	_
18	sites	_	_	NNS	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	blood	_	_	NN	_	_	_	_	_
21	vessels	_	_	NNS	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	such	_	_	JJ	_	_	_	_	_
24	as	_	_	IN	_	_	_	_	_
25	bends	_	_	NNS	_	_	_	_	_
26	or	_	_	CC	_	_	_	_	_
27	bifurcations	_	_	NNS	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	can	_	_	MD	_	_	_	_	_
30	cause	_	_	VB	_	_	_	_	_
31	local	_	_	JJ	_	_	_	_	_
32	activation	_	_	NN	_	_	_	_	_
33	of	_	_	IN	_	_	_	_	_
34	endothelial	_	_	JJ	_	_	_	_	_
35	cells	_	_	NNS	_	_	_	_	_
36	(	_	_	-LRB-	_	_	_	_	_
37	ECs	_	_	NNP	_	_	_	_	_
38	)	_	_	-RRB-	_	_	_	_	_
39	.	_	_	.	_	_	_	_	_


1	Consequently	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	ECs	_	_	NNP	_	_	_	_	_
4	acquire	_	_	VBP	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	pro-inflammatory	_	_	JJ	_	_	_	_	_
7	phenotype	_	_	NN	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	start	_	_	VB	_	_	_	_	_
10	expressing	_	_	VBG	_	_	_	_	_
11	different	_	_	JJ	_	_	_	_	_
12	pro-inflammatory	_	_	JJ	_	_	_	_	_
13	molecules	_	_	NNS	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	such	_	_	JJ	_	_	_	_	_
16	as	_	_	IN	_	_	_	_	_
17	monocyte	_	_	NN	_	_	_	_	_
18	chemotactic	_	_	JJ	_	_	_	_	_
19	protein	_	_	NN	_	_	_	_	_
20	1	_	_	CD	_	_	_	_	_
21	(	_	_	-LRB-	_	_	_	_	_
22	MCP1	_	_	NN	_	_	_	_	_
23	)	_	_	-RRB-	_	_	_	_	_
24	(	_	_	-LRB-	_	_	_	_	_
25	also	_	_	RB	_	_	_	_	_
26	known	_	_	VBN	_	_	_	_	_
27	as	_	_	IN	_	_	_	_	_
28	chemokine	_	_	NN	_	_	_	_	_
29	(	_	_	-LRB-	_	_	_	_	_
30	C-C	_	_	NN	_	_	_	_	_
31	motif	_	_	NN	_	_	_	_	_
32	)	_	_	-RRB-	_	_	_	_	_
33	ligand	_	_	NN	_	_	_	_	_
34	2	_	_	CD	_	_	_	_	_
35	;	_	_	:	_	_	_	_	_
36	CCL2	_	_	NN	_	_	_	_	_
37	)	_	_	-RRB-	_	_	_	_	_
38	,	_	_	,	_	_	_	_	_
39	intercellular	_	_	JJ	_	_	_	_	_
40	adhesion	_	_	NN	_	_	_	_	_
41	molecule	_	_	NN	_	_	_	_	_
42	1	_	_	CD	_	_	_	_	_
43	(	_	_	-LRB-	_	_	_	_	_
44	ICAM-1	_	_	NN	_	_	_	_	_
45	)	_	_	-RRB-	_	_	_	_	_
46	and	_	_	CC	_	_	_	_	_
47	vascular	_	_	JJ	_	_	_	_	_
48	cell	_	_	NN	_	_	_	_	_
49	adhesion	_	_	NN	_	_	_	_	_
50	molecule	_	_	NN	_	_	_	_	_
51	1	_	_	CD	_	_	_	_	_
52	(	_	_	-LRB-	_	_	_	_	_
53	VCAM-1	_	_	NN	_	_	_	_	_
54	)	_	_	-RRB-	_	_	_	_	_
55	,	_	_	,	_	_	_	_	_
56	all	_	_	DT	_	_	_	_	_
57	of	_	_	IN	_	_	_	_	_
58	which	_	_	WDT	_	_	_	_	_
59	attract	_	_	VBP	_	_	_	_	_
60	monocytes	_	_	NNS	_	_	_	_	_
61	to	_	_	TO	_	_	_	_	_
62	the	_	_	DT	_	_	_	_	_
63	activated	_	_	VBN	_	_	_	_	_
64	endothelium	_	_	NN	_	_	_	_	_
65	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	imbalance	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	monocyte/macrophage	_	_	NN	_	_	_	_	_
5	polarization	_	_	NN	_	_	_	_	_
6	towards	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	preferential	_	_	JJ	_	_	_	_	_
9	pro-inflammatory	_	_	JJ	_	_	_	_	_
10	phenotype	_	_	NN	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	lack	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	normal	_	_	JJ	_	_	_	_	_
16	inflammation	_	_	NN	_	_	_	_	_
17	resolution	_	_	NN	_	_	_	_	_
18	are	_	_	VBP	_	_	_	_	_
19	also	_	_	RB	_	_	_	_	_
20	present	_	_	JJ	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	atherosclerosis	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Phagocytic	_	_	JJ	_	_	_	_	_
2	macrophages	_	_	NNS	_	_	_	_	_
3	actively	_	_	RB	_	_	_	_	_
4	participate	_	_	VBP	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	lipid	_	_	JJ	_	_	_	_	_
7	accumulation	_	_	NN	_	_	_	_	_
8	by	_	_	IN	_	_	_	_	_
9	engulfing	_	_	VBG	_	_	_	_	_
10	lipid	_	_	NN	_	_	_	_	_
11	droplets	_	_	NNS	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	give	_	_	VB	_	_	_	_	_
14	rise	_	_	NN	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	foam	_	_	NN	_	_	_	_	_
17	cells	_	_	NNS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_
19	Dendritic	_	_	JJ	_	_	_	_	_
20	cells	_	_	NNS	_	_	_	_	_
21	(	_	_	-LRB-	_	_	_	_	_
22	DCs	_	_	NNS	_	_	_	_	_
23	)	_	_	-RRB-	_	_	_	_	_
24	contribute	_	_	VBP	_	_	_	_	_
25	to	_	_	TO	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	local	_	_	JJ	_	_	_	_	_
28	inflammatory	_	_	JJ	_	_	_	_	_
29	response	_	_	NN	_	_	_	_	_
30	through	_	_	IN	_	_	_	_	_
31	antigen	_	_	NN	_	_	_	_	_
32	presentation	_	_	NN	_	_	_	_	_
33	and	_	_	CC	_	_	_	_	_
34	cytokine	_	_	NN	_	_	_	_	_
35	signaling	_	_	NN	_	_	_	_	_
36	processes	_	_	NNS	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	If	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	inflammatory	_	_	JJ	_	_	_	_	_
4	process	_	_	NN	_	_	_	_	_
5	reaches	_	_	VBZ	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	resolution	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	repair	_	_	NN	_	_	_	_	_
10	processes	_	_	NNS	_	_	_	_	_
11	begin	_	_	VBP	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	plaque	_	_	NN	_	_	_	_	_
16	can	_	_	MD	_	_	_	_	_
17	become	_	_	VB	_	_	_	_	_
18	stable	_	_	JJ	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	failure	_	_	NN	_	_	_	_	_
4	to	_	_	TO	_	_	_	_	_
5	resolve	_	_	VB	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	inflammatory	_	_	JJ	_	_	_	_	_
8	response	_	_	NN	_	_	_	_	_
9	can	_	_	MD	_	_	_	_	_
10	result	_	_	VB	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	formation	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	most	_	_	RBS	_	_	_	_	_
17	dangerous	_	_	JJ	_	_	_	_	_
18	unstable	_	_	JJ	_	_	_	_	_
19	plaque	_	_	NN	_	_	_	_	_
20	that	_	_	WDT	_	_	_	_	_
21	can	_	_	MD	_	_	_	_	_
22	cause	_	_	VB	_	_	_	_	_
23	thrombosis	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	variety	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	immune	_	_	JJ	_	_	_	_	_
7	cells	_	_	NNS	_	_	_	_	_
8	are	_	_	VBP	_	_	_	_	_
9	involved	_	_	VBN	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	atherosclerosis	_	_	NN	_	_	_	_	_
12	initiation	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	progression	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	review	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	we	_	_	PRP	_	_	_	_	_
6	consider	_	_	VBP	_	_	_	_	_
7	main	_	_	JJ	_	_	_	_	_
8	subsets	_	_	NNS	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	pro-	_	_	JJ	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	anti-inflammatory	_	_	JJ	_	_	_	_	_
13	immune	_	_	JJ	_	_	_	_	_
14	cells	_	_	NNS	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	myeloid	_	_	JJ	_	_	_	_	_
17	origin	_	_	NN	_	_	_	_	_
18	that	_	_	WDT	_	_	_	_	_
19	contribute	_	_	VBP	_	_	_	_	_
20	to	_	_	TO	_	_	_	_	_
21	atherogenesis	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_

